Home > Products > Human Tumor Cell Lines >
OE33 | ||||
|---|---|---|---|---|
| Product Name | OE33 | |||
| Price | Get Quote | |||
| Product Code | OE-33; JROECL 33; JROECL33; OEC33 | |||
| Cat.No | ABC-TC510S | Species | Human | |
| Size/Quantity | 1 vial | |||
| Shipping Info | Dry Ice | Storage | Liquid Nitrogen | |
| Description |
Why choose OE33 from AcceGen? The OE33 cell line from AcceGen offers exceptional features, characterized by its high viability and quality, cultivated under ideal conditions. It maintains sterility and consistently tests negative for bacteria, yeast, mycoplasma, and a spectrum of pathogens including HIV, HBV, HCV, HPV, HTLV, and MLV. Identity verification is assured through STR analysis, and stringent quality control measures further guarantee its reliability. | |||
| Disease | Esophageal Cancer | |||
| Source Organ | Esophagus | |||
| Recommended Medium And Supplement | RPMI 1640 + 10% FBS | |||
| Citation Guide | When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID). | |||
| Application | FOR RESEARCH USE ONLY The OE33 cell line serves as a valuable, continuous resource for both research and therapeutic advancement in the realm of esophageal adenocarcinoma. It plays a pivotal role in the investigation of the disease, aiding in a deeper understanding of its pathogenesis and progression. Moreover, OE33 cells are instrumental in the development of innovative treatment strategies for esophageal adenocarcinoma, serving as an indispensable tool for preclinical drug testing and the exploration of potential therapeutic interventions, ultimately contributing to improved patient outcomes in the battle against this challenging malignancy. | |||
| Growth Conditions | 37 ℃, 5% CO2 | |||
| Cell Type | Epithelial | |||
| Growth Mode | Adherent | |||
| Product Type | Human Esophageal Cancer Cell Lines | |||
| Product Image |  | |||
The OE33 cell line, also known as JROECL33, was established from a 73-year-old female patient with adenocarcinoma originating in the lower esophagus, specifically associated with Barrett’s metaplasia. The tumor was diagnosed as pathological stage IIA (UICC) and exhibited poor differentiation. OE33 cells continuously express HLA-A, -B, and -C antigens (MHC class I), along with ICAM-1. The introduction of interferon-gamma can induce the expression of HLA-DR (MHC class II) in these cells. They display epithelial cytokeratins such as CK7, CK8, CK18, and CK19, while CK17 is notably absent. Moreover, OE33 cells express EpCAM but lack desmin, endothel, GFAP, neurofilament, and vimentin. Notably, they possess tumorigenic potential when transplanted into nude mice.- ONLINE INQUIRY
- PRODUCT REVIEWS
Fill out a request in the form below and we’ll get back to you within 24 hours with a quote.
